CRISPR Therapeutics(CRSP) - 2024 Q2 - Quarterly Results

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results -More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July- -Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively, across multiple indications- -Clinical trials opened for CTX112 in systemic lupus erythematosus (SLE) a ...